Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial

Por Hui, R., Garon, E. B., Goldman, J. W., Leighl, N. B., Hellmann, M. D., Patnaik, A., Gandhi, L., Eder, J. P., Ahn, M.-J., Horn, L., Felip, E., Carcereny, E., Rangwala, R., Lubiniecki, G. M., Zhang, J., Emancipator, K., Roach, C., Rizvi, N. A.
Publicado no Ann Oncol (2017)